459 related articles for article (PubMed ID: 29122465)
1. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
[TBL] [Abstract][Full Text] [Related]
5. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
6. Assessment of patients post reversal with idarucizumab.
Raco V; Ahuja T; Green D
J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
8. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
Sheikh-Taha M
Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
[TBL] [Abstract][Full Text] [Related]
10. Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
Giannandrea D; Mengoni A; Carluccio E; Ambrosio G
Vasc Health Risk Manag; 2019; 15():139-142. PubMed ID: 31213821
[TBL] [Abstract][Full Text] [Related]
11. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
[TBL] [Abstract][Full Text] [Related]
12. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
[TBL] [Abstract][Full Text] [Related]
13. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N; Morrill AM; Willett KC
Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
[TBL] [Abstract][Full Text] [Related]
14. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
[TBL] [Abstract][Full Text] [Related]
15. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
Pollack CV
Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
[TBL] [Abstract][Full Text] [Related]
17. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
18. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
Levy JH; van Ryn J; Sellke FW; Reilly PA; Elsaesser A; Glund S; Kreuzer J; Weitz JI; Pollack CV
Ann Surg; 2021 Sep; 274(3):e204-e211. PubMed ID: 31599808
[TBL] [Abstract][Full Text] [Related]
20. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Althaus K; Berrouschot J; Cangür H; Daffertshofer M; Edelbusch S; Gröschel K; Haase CG; Harloff A; Held V; Kauert A; Kraft P; Lenz A; Müllges W; Obermann M; Partowi S; Purrucker J; Ringleb PA; Röther J; Rossi R; Schäfer N; Schneider A; Schuppner R; Seitz RJ; Szabo K; Wruck R
Int J Stroke; 2017 Jun; 12(4):383-391. PubMed ID: 28494694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
